Merck, BMS Target Cipla USA Over Generic HIV Drug Sustiva

Law360, New York (June 28, 2013, 7:08 PM EDT) -- Merck Sharp & Dohme Corp. and Bristol-Myers Squibb Co. brought patent infringement allegations in New Jersey federal court Thursday against Indian generics maker Cipla USA Inc. over the company’s plans to make a generic version of the HIV treatment Sustiva.

BMS alleges Cipla has infringed two patents related to the HIV drug by submitting an abbreviated new drug application seeking U.S. Food and Drug Administration approval to make a generic form of Sustiva.

Merck is the assignee of the two patents, but under an agreement, BMS...
To view the full article, register now.